Risk of Prostate Cancer–Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy

Abstract

Clinical parameters (PSADT, pathological Gleason score, and time from surgery to biochemical recurrence) can help risk stratify patients for prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. These preliminary findings may serve as useful guides to patients and their physicians to identify patients at high risk for prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy to enroll them in early aggressive treatment trials. In addition, these preliminary findings highlight that survival in low-risk patients can be quite prolonged.

Long‐term overall survival and metastasis‐free survival for men with prostate‐specific antigen‐recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database

“…When examining risk factors for metastasis and death in the present study, only the PSADT emerged as an independently prognostic indicator for both outcomes on multivariate analysis. This finding was in contrast to the Johns Hopkins data, where pathological Gleason score and time to PSA relapse were also independently associated with MFS [13] (although the latter was not confirmed in the updated analysis [14]) and OS [15]. This discrepancy may be a true difference or it may be the result of a smaller sample size in the present study and fewer events (metastases and deaths).…”

Integrated proteogenomics uncovers ancestry-specific and shared molecular drivers in localized prostate cancer

“…A median follow-up time of over 10 years enabled meaningful analysis of clinical endpoints. The overall biochemical recurrence (BCR) rate of 26% and metastasis rate of 11% are consistent with other recorded cohorts 25,26 .…”

Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer

“…This study identified the biopsy Gleason score at initial diagnosis as a prognostic factor for castration resistance, especially for patients treated with radical prostatectomy. This finding is consistent with a previous report that the biopsy Gleason score at initial diagnosis before radiotherapy (10) and the pathological Gleason score at radical prostatectomy (15)(16)(17) are prognostic factors for disease recurrence. Moreover, we found that PSA level and PSA velocity at ADT initiation were prognostic factors for men treated with radiotherapy.…”